

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE


Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand: explanatory leaflet available from ADONIS BV, PO Box 839, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

Indexed & abstracted by **CURRENT CONTENTS/Social & Behavioral Sciences (Social Science CITATION INDEX, Research Alert), EXCERPTA MEDICA (EMBASE), PSYCHOLOGICAL ABSTRACTS (PsycINFO, PsycLIT), BIOLOGICAL ABSTRACTS/RRM (BIOSIS Previews); Cumulative Index to Nursing and Allied Health Literature, Linguistics and Language Behavior Abstracts, Nutrition Abstracts and Reviews (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, and Sociological Abstracts.**

Front cover description p. 49
John Dunne Medal p. 78




Modecate Abbreviated Prescribing Information. Indications: Treatment of psychotic disorders. **Dosage – Modecate injection 25mg/ml.** Most patients are successfully maintained within the dosage range 12.5mg (0.5ml) every five weeks to 100mg (4ml) every two weeks. For full dosage information see Data Sheet. **Modecate concentrate injection 100mg/ml.** Adult patients found to require larger volumes of Modecate 25mg/ml may be transferred directly to the equivalent dose of Modecate concentrate on the basis that 1ml Modecate concentrate is equivalent to 4ml Modecate. **Contra-indications.** Patients with marked cerebral atherosclerosis, phaeochromocytoma, renal or liver failure, or severe cardiac insufficiency. **Precautions.** Care should be taken in patients, particularly the elderly, who exhibit marked extrapyramidal reactions to oral phenothiazines. **Side effects.** Mainly extrapyramidal reactions. Drowsiness, lethargy, dryness of the mouth and mild hypotension may occur. **Product Licence No's and Prices.** **Modecate injection 25mg/ml.** PL 0034/5046. 10 x 1ml ampoule £25.20 **Modecate concentrate injection 100mg/ml.** PL 0034/0189. 10 x 0.5ml ampoule £49.99 5 x 1.0ml ampoule £48.86. Modecate is a Trade Mark of E. R. Squibb & Sons Ltd. Further information available from: Technical Services Department, E. R. Squibb & Sons Ltd., 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel: 01-572 7422.



TRIED AND TRUSTED

19 years ago, E. R. Squibb & Sons helped lead a revolution in the community based treatment of schizophrenia when they introduced the depot neuroleptic concept. Since then worldwide clinical experience has confirmed the efficacy and safety of Modecate in over 800,000 patients. Modecate is now regarded by many psychiatrists as the standard depot neuroleptic.



Modecate is available in two strengths, allowing a wide dosage range with convenient injection volumes. Most patients can be controlled with an injection at intervals of 3 weeks or more.¹ Modecate is less expensive than other depot neuroleptics when comparing equipotent doses.

1) Johnson DAW Br J Psychiat 1975; 126: 457-461.

E. R. Squibb & Sons Ltd., 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel: 01-572 7422.



CONTENTS

EDITORIAL

- AIDS and mental health** 3
Norman Sartorius

ORIGINAL PAPERS

- Manic-depressive illness – I: clinical characteristics of bipolar disorder subtypes** 6

- Manic-depressive illness – II: treatment outcome in bipolar disorder subtypes** 9

Patrick McKeon, Patrick Manley, Gregory Swanwick

- Primary care based psychiatric clinics: observations on a one year cohort of referrals** 13

Stephen J Cooper, Andrew Gilliland, Sinead McGilloway, Michael Doherty, Elizabeth Cormac

- The role of the child psychiatric ward in health care: experience with different types of admissions over a period of twenty-one years** 17

Colin Gray, Douglas Chisholm, Patricia Smith, Madeline Brown, Christina McKay

- Emotionalism in Parkinson's disease** 24

Peter Madeley, Colin Anthony Biggins, Jane L Boyd, Richard H S Mindham, Ernest G S Spokes

- The manic readmissions explosion in Edinburgh** ... 26

Anthony J Mander

- "War neurosis" and associated physical conditions** . 30

Ian P Burges Watson, George V Wilson, Helen Hornsby

- Diogenes syndrome – an Irish series** 37

Margo Wrigley, Colm Cooney

CLINICAL AND BRIEF REPORTS

- Post traumatic stress disorder symptoms in prisoners following a cell mate's hanging** 42

Aideen Freyne, Art O'Connor

- Transsexualism in a Klinefelter male: a case report**.. 45

Elizabeth M J Cryan, Frank P O'Donoghue

- Command hallucinations, schizophrenia and sexual assaults** 47

Gareth Jones, Phil Huckle, Amgad Tanaghaw

- Psychotropic management of seizure duration during electroconvulsive therapy: trazodone, a case report** . 50

Kenneth R Kaufman, Ettie R Kaufman

- Delusional dish syndromes** 52

Brian Kidd, Robin McGilp, Cameron Stark, Joseph P McKane

- Remarkable resolution of an uncommon psychosyndrome: epilepsy-induced remission of Cotard's syndrome** 53

Kevin Malone, John P Malone

- Reversal of roles in folie a deux associated with manic-depressive illness** 55

C M Dymrna Ryan, Shaukat A Khan, Hilary M C Warwick, Richard H S Mindham

- The Hillsborough football stadium disaster: a single case study** 57

Raymond F Travers, Gus A Baker

- Lithium toxicity, hypomania and leucocytosis with fluoxetine** 59

Padraig Wright, Ram Seth

PERSPECTIVE

- The phenomena of "bingeing"** 61

Clive G Ballard, Ramilgan N C Mohan, Laurence McGibben, Matthew Kurian, W Raza Silveira

PRACTICE REVIEWS

- Medical audit in an elderly depressed cohort** 62

Peter Donnelly

- Psychiatric hospital staff knowledge and attitudes towards AIDS, and the impact of an in-house education seminar** 67

Ronan J McIvor, Rory K Shelley

HISTORICAL

- Korsakov** 70

Caoimhghin S Breathnach

LETTERS TO THE EDITOR

- Lithium in resistant depression** 71

Albert Michael, Alphie Pallen, Katherine Brown

- Psychiatrists' use of antidepressants: preferences versus toxicity** 72

David Lester; Brian O'Shea (Author's reply)

- BOOK REVIEWS** 73

- Royal Academy of Medicine in Ireland, Psychiatry Section: Registrars' Research Competition winner** .. 25

- Guidelines for authors** 41

- Index to advertisers** 66

Editor in Chief: Mark Hartman (Dublin). **Editors:** Timothy Dinan (Dublin), Roy McClelland (Belfast). **Associate Editors:** Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Ethna O'Gorman (Belfast), Brian O'Shea (Dublin). **Assistant Editors:** Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), David King (Belfast), Brian Leonard (Galway), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary). **Statistical Editor:** Leslie Daly (Dublin). **Managing Editor:** Aidan McGennis (Dublin).

PRINTING AND TYPESETTING: Turner Print Group, Longford & Dublin. COVER DESIGN: Martina Leonard. CIRCULATION: 4,000 to 54 countries. Journal participates in the World Health Organization project to improve the distribution of scientific materials on mental health. FREQUENCY: Twice yearly (May & November) SUBSCRIPTION RATES (Annual): £42 Europe, \$84 outside Europe, including postage. ADDRESS: Submissions & correspondence to the Editor, Irish Journal of Psychological Medicine, St. Brendan's Hospital, Rathdown Road, Dublin 7, Ireland. Tel: (088)-578406; International: +353-(88)-578406. Fax: (01)-280 0504; Int: +353-(1)-280 0504. PUBLISHER: Irish Institute of Psychological Medicine Ltd. Publication does not imply endorsement. Limited photocopying authorization granted for a fee to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA, or to appropriate Reproduction Rights Organization; isolated, non-profit, academic photocopying excepted.



PROZAC REPUBLIC OF IRELAND ABBREVIATED PRESCRIBING INFORMATION
(FLUOXETINE HYDROCHLORIDE)

Presentation Capsules containing 20mg fluoxetine hydrochloride.
Uses Treatment of the symptoms of depressive illness.
Dosage and Administration:
 (For full information, see data sheet)
 For oral administration to adults only.
Depression: A dose of 20mg/day is recommended. Because of the long elimination half-lives of the parent drug and its major metabolite, changes in dose will not be fully reflected in plasma for several weeks.
Bulimia: A dose of 60mg/day is recommended.
 The maximum daily dose should not exceed 80mg for any indication.
The elderly: The maximum total daily dose should not exceed 40mg.
Children: Not recommended.
Patients with renal and/or hepatic dysfunction: See 'Contra-indications' and 'Precautions' sections.
Contra-indications, Warning, etc.: Contra-indications: Hypersensitivity to fluoxetine. Prozac should not be administered to patients with severe renal failure (GFR <10ml/min). Unstable epilepsy or convulsant disorders.
Use in conjunction with monoamine oxidase inhibitors: At least 14 days should elapse between discontinuation of an MAOI and initiation of treatment with Prozac. At least five weeks should elapse between discontinuation of Prozac and initiation of therapy with an MAOI.
Serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) have been reported with concomitant use or when fluoxetine has been recently discontinued and an MAOI started. Cyproheptadine or dantrolene may benefit patients experiencing such reactions.
Use in nursing mothers: Prozac should not be prescribed to nursing mothers.
Warnings: Rash and possibly allergic events: Prozac should be discontinued upon appearance of rash or of other possibly allergic phenomena for which an alternative aetiology cannot be identified. Systemic events, possibly related to vasculitis, have developed. Although rare, this may be serious, involving lung, kidney or liver. Death has occurred. Serum sickness, anaphylaxis and pulmonary events, including inflammatory processes and/or fibrosis, have been reported.
Use in pregnancy: The safety of Prozac in human pregnancy has not been established.
Precautions: Prozac should be avoided in patients with unstable epilepsy (see 'Contra-indications') and it should be discontinued in any patient who develops seizures.
 A lower dose of Prozac, e.g. alternate day dosing, is recommended in patients with significant hepatic dysfunction or mild to moderate renal failure (GFR 10-50ml/min).
 Caution is advisable when Prozac is used in patients with acute cardiac disease.
 Prozac may cause weight loss which may be undesirable in underweight depressed patients.
 In diabetes, fluoxetine may alter glycaemic control.
 There is little clinical experience of the concurrent administration of fluoxetine with ECT or lithium therapy (See 'Drug interactions'). There have been case reports of prolonged seizures in patients on fluoxetine receiving ECT treatment.
 Rare reports of altered platelet function and/or abnormal laboratory values, and several reports of abnormal bleeding.

SEE THE PROBLEM
IN A NEW LIGHT

Prozac 20mg
Once daily



IN DEPRESSION

fluoxetine
PROZAC

Drug interactions: Monoamine oxidase inhibitors - see 'Contra-indications'.
 Greater than 2-fold increases of previously stable plasma levels of other antidepressants have been observed when Prozac has been administered in combination.
 Agitation, restlessness and gastrointestinal distress have been reported in five patients receiving fluoxetine in combination with tryptophan.
 Increased (with lithium toxicity) or decreased lithium levels have been reported. Lithium levels should be monitored.
Pharmacokinetic data suggest that the half-life of diazepam may be prolonged in some patients. For further information, see data sheet.
Side-effects: Depression. The following treatment-emergent adverse events were observed during placebo controlled clinical trials at a frequency of one per cent or greater and at a significantly higher incidence than placebo (P value <0.05).
 Anorexia, fever, nausea, diarrhoea, mouth dryness, appetite loss, dyspepsia, headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, fatigue, decreased libido, pharyngitis, dyspnoea, excessive sweating, (rash, see 'Warnings'), sexual dysfunction.
Bulimia: Using the same criteria, insomnia, nausea, anorexia, tremor, sweating, decreased libido.
 The more common events listed above that caused discontinuation include nausea, headache, nervousness, insomnia, anxiety, dizziness and anorexia.
 Other events that have been reported include vomiting, diphtheria, hallucinations, psychosis and convulsions.
 During pre-marketing testing hypomania or mania occurred in approximately 1 per cent of fluoxetine treated patients.
 Elevated serum transaminase values and/or depressed leucocyte counts without accompanying symptoms occurred infrequently in patients given fluoxetine.
 Voluntary reports of adverse events temporally associated with fluoxetine, that have been received since market introduction and which may have no causal relationship with the drug, include: cerebral vascular accident, convulsions, dyskinesia, ecchymoses, gastro-intestinal haemorrhage, hyperproliferation, pancreatitis, suicidal ideation, thrombocytopenia, thrombocytopenic purpura, vaginal bleeding after drug withdrawal and violent behaviours.
Hypotension (including serum sodium below 110mmol/l) has been rarely reported. This appears to be reversible upon discontinuation.
 Any adverse reactions or events should be reported to the NDAB.
Overdosage: As of December 1987, there have been 2 deaths in patients who took overdoses of fluoxetine in combination with other drugs (maprotiline, clobazam, zolamepam). Except for these deaths, all other 36 overdose cases which involved fluoxetine either alone or in combination with other drugs and/or alcohol recovered without complications.
 One patient who reportedly took 3000mg of fluoxetine experienced 2 grand mal seizures that remitted spontaneously.
 Since introduction, a single death, attributed to overdose of fluoxetine alone, has been reported.
 Legal Category: S.I.A. Product Authorisation Number: 4475/1
 Date of Preparation or Last Review: February 1991
 Further information is available from: Eli Lilly & Co Ltd, 3 Kingham Place, Dublin 2. Telephone: Dublin 614377 or 614475
 PROZAC is a trademark
 PZ244MAR/91

